StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$11.25−0.48 (-4.09%)

Close on Nov 17, 2026Market cap $957.45MP/E –Yield –

MoonLake Immunotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for MoonLake Immunotherapeutics

MoonLake Immunotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More MoonLake Immunotherapeutics figures

See a number that looks wrong?